These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 21748762)

  • 1. Role of cyclophilin B in tumorigenesis and cisplatin resistance in hepatocellular carcinoma in humans.
    Kim Y; Jang M; Lim S; Won H; Yoon KS; Park JH; Kim HJ; Kim BH; Park WS; Ha J; Kim SS
    Hepatology; 2011 Nov; 54(5):1661-78. PubMed ID: 21748762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
    Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
    Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Akt/hypoxia-inducible factor-1alpha/platelet-derived growth factor-BB autocrine loop mediates hypoxia-induced chemoresistance in liver cancer cells and tumorigenic hepatic progenitor cells.
    Lau CK; Yang ZF; Ho DW; Ng MN; Yeoh GC; Poon RT; Fan ST
    Clin Cancer Res; 2009 May; 15(10):3462-71. PubMed ID: 19447872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
    Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
    Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.
    Xu H; Zhao L; Fang Q; Sun J; Zhang S; Zhan C; Liu S; Zhang Y
    PLoS One; 2014; 9(12):e115565. PubMed ID: 25531114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canagliflozin Modulates Hypoxia-Induced Metastasis, Angiogenesis and Glycolysis by Decreasing HIF-1α Protein Synthesis via AKT/mTOR Pathway.
    Luo J; Sun P; Zhang X; Lin G; Xin Q; Niu Y; Chen Y; Xu N; Zhang Y; Xie W
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human carbonyl reductase 1 upregulated by hypoxia renders resistance to apoptosis in hepatocellular carcinoma cells.
    Tak E; Lee S; Lee J; Rashid MA; Kim YW; Park JH; Park WS; Shokat KM; Ha J; Kim SS
    J Hepatol; 2011 Feb; 54(2):328-39. PubMed ID: 21056497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIF-1α-induced RIT1 promotes liver cancer growth and metastasis and its deficiency increases sensitivity to sorafenib.
    Song Z; Liu T; Chen J; Ge C; Zhao F; Zhu M; Chen T; Cui Y; Tian H; Yao M; Li J; Li H
    Cancer Lett; 2019 Sep; 460():96-107. PubMed ID: 31247273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of PI3 kinase/Akt/HIF-1α pathway contributes to hypoxia-induced epithelial-mesenchymal transition and chemoresistance in hepatocellular carcinoma.
    Jiao M; Nan KJ
    Int J Oncol; 2012 Feb; 40(2):461-8. PubMed ID: 21922131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sanguinarine inhibits epithelial-mesenchymal transition via targeting HIF-1α/TGF-β feed-forward loop in hepatocellular carcinoma.
    Su Q; Fan M; Wang J; Ullah A; Ghauri MA; Dai B; Zhan Y; Zhang D; Zhang Y
    Cell Death Dis; 2019 Dec; 10(12):939. PubMed ID: 31819036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo.
    Moser C; Lang SA; Mori A; Hellerbrand C; Schlitt HJ; Geissler EK; Fogler WE; Stoeltzing O
    BMC Cancer; 2008 Jul; 8():206. PubMed ID: 18651980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The transcription factor ZFHX3 is crucial for the angiogenic function of hypoxia-inducible factor 1α in liver cancer cells.
    Fu C; An N; Liu J; A J; Zhang B; Liu M; Zhang Z; Fu L; Tian X; Wang D; Dong JT
    J Biol Chem; 2020 May; 295(20):7060-7074. PubMed ID: 32277050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Periostin contributes to arsenic trioxide resistance in hepatocellular carcinoma cells under hypoxia.
    Liu Y; Gao F; Song W
    Biomed Pharmacother; 2017 Apr; 88():342-348. PubMed ID: 28119236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PFKFB3/HIF-1α feedback loop modulates sorafenib resistance in hepatocellular carcinoma cells.
    Long Q; Zou X; Song Y; Duan Z; Liu L
    Biochem Biophys Res Commun; 2019 Jun; 513(3):642-650. PubMed ID: 30981500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bclaf1 promotes angiogenesis by regulating HIF-1α transcription in hepatocellular carcinoma.
    Wen Y; Zhou X; Lu M; He M; Tian Y; Liu L; Wang M; Tan W; Deng Y; Yang X; Mayer MP; Zou F; Chen X
    Oncogene; 2019 Mar; 38(11):1845-1859. PubMed ID: 30367150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin suppresses hypoxia-induced stabilization of HIF-1α through reprogramming of oxygen metabolism in hepatocellular carcinoma.
    Zhou X; Chen J; Yi G; Deng M; Liu H; Liang M; Shi B; Fu X; Chen Y; Chen L; He Z; Wang J; Liu J
    Oncotarget; 2016 Jan; 7(1):873-84. PubMed ID: 26621849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma.
    Liu LP; Ho RL; Chen GG; Lai PB
    Clin Cancer Res; 2012 Oct; 18(20):5662-71. PubMed ID: 22929805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant canstatin inhibits the progression of hepatocellular carcinoma by repressing the HIF-1α/VEGF signaling pathway.
    Zhu L; Ao L; Guo Z; Yang Y; Wang Z; Gu Z; Xin Y; Zhou L; Zhang L
    Biomed Pharmacother; 2024 Oct; 179():117423. PubMed ID: 39260328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIPK2 suppresses tumor growth and progression of hepatocellular carcinoma through promoting the degradation of HIF-1α.
    Chen P; Duan X; Li X; Li J; Ba Q; Wang H
    Oncogene; 2020 Apr; 39(14):2863-2876. PubMed ID: 32034309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia inducible factor in hepatocellular carcinoma: A therapeutic target.
    Lin D; Wu J
    World J Gastroenterol; 2015 Nov; 21(42):12171-8. PubMed ID: 26576101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.